ABSTRACT-Strontium at low doses has been used to treat osteoporosis. However, excessive doses can disturb calcium metabolism. The aim of the present study was to determine a dose that does not have any significant toxic effects on calcium contents in bone and calcium metabolism, and, consequently, to distinguish between pharmacological and toxic doses in rats. The rats were divided into a control, 0.05% Sr, 0.10%-Sr and 0.50%-Sr groups (strontium intake approx. 0, 87.5, 175 and 875 pcmol/day, respectively). All of the rats were pair-fed their respective diets containing various doses of strontium in single metabolic cages from when they were 36 to 63 days old. When the rats were 60 days old, bone formation, bone resorp tion, calcium balance and intestinal calcium absorption were calculated as calcium metabolic parameters over a 3-day period using calcium balance and kinetic studies. At the age of 64 days, the rats were sacrificed under anesthesia, and the femur and blood were collected. Calcium and strontium levels in the bone and serum were then measured. In the strontium groups that received less than 175 pmol/day, none of the calcium metabolic parameters were significantly affected. However, the calcium contents in the bone were significantly increased in the group that received 87.5 pmol/day group. On the other hand, in the group that received the highest dose of strontium (875 pmol/day), all of the calcium metabolic parameters measured were markedly suppressed. A decrease in calcium level in both the bone and serum was also observed. These results suggest that strontium at doses of less than 175 , imol per day does not have a toxic effect on calcium contents in bone or calcium metabolism in rats, and a dose of 87.5 pmol/day may be adopted for future evaluations of the efficacy of strontium in various experimental skeletal diseases.
Administration
of excessive doses of strontium to animals has been shown to reduce intestinal calcium ab sorption (1) (2) (3) (4) (5) and to induce hypocalcaemia and/or hypocalcified bone (2, (4) (5) (6) (7) . These changes in calcium metabolism are thought to be induced indirectly by depres sion of la,25-dihydroxyvitamin D3 synthesis (2, 8, 9) . It has recently been reported that strontium accumulated in bone directly reduces bone resorption and/or formation at toxic dose levels in vivo (4) and in vitro (5) . In addition to these toxic effects of strontium, clinical beneficial effects have been reported by Skoryna and Fuskova in that low doses of strontium remineralize skeletal lesions and increase bone mass in patients with metastatic bone cancer. These authors have drawn a distinction between pharmacological and toxic levels in strontium therapy (10) . In addition, it has also been reported that patients with osteoporosis show a favorable response to treatment with strontium (11) . These beneficial effects (10, 11) are mainly assessed by radiographic findings, and the mecha nism of these effects is still unclear. A few animals studies support the beneficial effects of strontium. Marie et al. (12) reported that an augmentation of trabecular bone volume is induced by low doses of strontium without any changes in serum la,25-dihydroxyvitamin D3 in rats. They suggested that strontium directly suppresses bone resorption, and that strontium may have beneficial effects on skeletal lesions.
The general procedure for a calcium balance and kinet ics study was originally described by Aubert and Milhaud (13) . The method is based on the measurement of the in take and excretion of stable calcium and of the kinetics of injected 41 Ca during a 72-hr period. Using this method, many parameters of calcium metabolism, such as intake, intestinal absorption, intestinal and urinary excretion, and deposition and resorption of bone, can be deter mined or estimated. The highly integrated and complex calciotropic hormones and cytokines regulate the flow of minerals into and out of the extracellular fluid compart ment at each organ. Bone mineral metabolism may be affected not only by drugs but also by changes in mineral flow in various organs. In most of the previous studies , food was available ad libitum, and strontium was ad ministered in either food or drinking water, so that the amount of strontium and calcium intake were not con trolled. We assessed the effects of a low dose of strontium in rats that were fed diets that were identical, except with regard to the amount of strontium (pair-feeding). The aims of this experiment were to estimate the minimum toxic dose of strontium and to investigate the effects of strontium at levels less than this toxic dose in young growing rats. 
MATERIALS AND METHODS

Animals and feeding plan
Twenty-seven female Wistar rats (88-109 g b.wt.) were divided into four groups: a control group (n=6) , a 0.05 %-Sr group (n=6), a 0.10%-Sr group (n=7) and a 0.50%-Sr group (n=8). The rats in the control group were fed a semi-synthetic vitamin D-deficient diet contain ing 0.5 w/w% calcium (125 mmol calcium/kg of dry diet) and 0.35 w/w% phosphorus (4). The strontium-fed groups were fed diets similar to those of the control group, but to which strontium carbonate (SrCO3) had been added. All of the rats were given distilled water ad libitum, and 10 IU of vitamin D3 dissolved in 0.1 ml of cottonseed oil was placed on each diet every day just be fore feeding. The diets described above were given to the rats in the respective groups from when they were 36 to 63 days old. All of the rats were pair-fed each diet in single metabolic cages. When the rats were 36 to 45 days old, the amount of diet given was increased each day to match the growth of the rats in each group . All of the rats were given 0.92 mmol calcium/day at the age of 36 days and 1.73 mmol calcium/day at the age of 45 days. Thereafter, the cal cium supply was constant (1.75 mmol calcium/day). The treatment of the experimental animals was approved by the Experimental Animal Committee of Showa Univer sity.
Calcium and strontium metabolic studies Calcium balance and kinetic studies were performed to examine the effect of strontium on calcium metabolism, using the method described by Aubert and Milhaud (13) . Briefly, this method involves the examination of the in take and excretion of calcium and the measurement of the kinetics of injected 45Ca over a 3-day period. The decay of the specific activity of 45Ca in plasma was fitted to a dou ble exponential function and analyzed according to the two-compartment model for calcium metabolism. In the present investigation, a strontium balance study was also performed to measure the intake and excretion of stron tium. The parameters in the metabolic studies are de scribed in Table 1 .
When the rats were 60 days old, 1.11 MBq of 45CaC12 solution (radioactivity of approximately 37 MBq/ml) in 0.3 ml of 0.15 M NaCl was injected into the tail vein of each rat. Blood samples were obtained from the tail at 2, 4, 6, 25, 49 and 73 hr after the injection. The amount of 41 Ca in these samples was determin ed by using a liquid scintillation counter (Model 3255; Packard Instrument Company, Inc., Meriden, CT, USA). The amount of diet consumed by each rat was noted. Urine and feces were harvested on sheets of filter paper over the 3-day period. The feces and filter papers that contained urine were ashed and then dissolved in 2.0 N HCI. Aliquots of these urine and feces sample solutions were counted for 45Ca. The amount of calcium and strontium in the feces, and the amount of strontium in the urine were also deter mined by an atomic absorption spectrophotometer (Model 603; Perkin Elmer Co., Ltd., Norwalk, CT, USA) or by EGTA titration (Corning calcium analyzer 940; Corning Co., Ltd., Corning, NY, USA). The concentra tions of calcium and strontium in the serum were meas ured at the end of the experiment.
Calcium and strontium contents in bone and histological studies When the rats were 64 days old, they were sacrificed un der ether anesthesia, and their femurs were removed and fixed and defatted in 70% ethanol. Radiograms of the femurs in each group were taken with a soft X-ray appara tus (SOFRON type SRO-M50; Sofron Co., Ltd., Tokyo) to examine the degree of ossification and to note the bone length. The bones were then dried and ashed to measure calcium and strontium contents in the bone.
Statistical analyses All of the results are expressed as the mean -L S.D., and the significance of the differences between the values of the control, 0.05%-Sr, 0.10%-Sr and 0.50%-Sr groups was evaluated by Student's t-test. 
RESULTS
Animal growth There were no significant differences in growth among the control and strontium-fed groups (Fig. 1) . In addi tion, no adverse effects were found in the extremities, such as an inability to stand or paralysis (14) .
Calcium metabolism
The results of the calcium balance and kinetic studies are shown in Fig. 2 Net intestinal calcium absorption (Vna) and the fractional calcium absorption (ii) were mark edly decreased in the 0.50%-Sr group (Fig. 2, b and c) .
The values of Vna and ~ in the 0.50%-Sr groups were about 80% of those in the control group. Furthermore, in the 0.50%-Sr group, marked decreases in the skeletal parameters, such as bone formation (Vo +), bone resorp tion (Vo-) and calcium retention in the body (Vd) were observed ( Fig. 2; d, e and f). However, no significant changes were observed in either of the other strontium groups.
Strontium metabolism
The results of the strontium balance study are shown in Fig. 3 . Strontium absorption in the intestine (sVna) was proportional to the strontium intake (sVi). However, as opposed to the intestinal calcium absorption ratio (~), there was no significant correlation in the strontium ab sorption ratio (sp). Strontium was retained in the body (sVd) in proportion to the strontium intake (sVi).
Analysis of minerals in blood and femur, and radiograph ic findings Hypocalcaemia was observed in the 0.50%-Sr group. However, normal serum calcium levels were observed in the other groups (Table 2) . Serum strontium levels in the strontium-fed groups increased in a dose-dependent man ner: i.e., approx. 68 tiM, 175 1iM and 550 pM, respective ly (Fig. 3a) . Calcium contents in ashed and dried-femur increased moderately, but significantly, in the 0.05 %-Sr group (P<0.05), remained unchanged in the 0.10%-Sr group, and decreased significantly in the 0.50%-Sr group. The total amounts of calcium and strontium (in terms of molarity) and the length of the femur in the strontium-fed groups were not significantly different than those in the control group ( Table 2) . As seen in Fig. 4 , a large amount of trabecular bone was observed in the 0.50%-Sr group.
DISCUSSION
In the present study, the amount of calcium consumed in each group was almost identical (Fig. 2a) , and the body weights of the rats in the strontium-fed groups matched those in the control group (Fig. 1) .
In a previous study, when rats received a relatively low dose of strontium (0.0027 to 0.157% in the diet), stron tium concentrations in bone reached a constant level after only 4 weeks of dietary treatment (15) . These findings show that calcium and strontium metabolism in the rats had reached a steady state. Such a steady state condition is required for a calcium kinetics study. Thus, the dura tion of dietary treatment in the present study was consi dered adequate for investigating the effects of strontium. Table 1 . The parameters are explained in Table 1 . Fig. 4 . Effect of dietary strontium on rat femoral radiography after 4 weeks on the control or strontium diets. The strontium fed groups, 0.05, 0.10 and 0.50%-Sr groups, consumed strontium at the dose of 87.5, 175 and 875 pmol per day, respectively. Calcium intake in each group was constant (1.75 mmol per day). In the 0.5%-Sr group, a large amount of trabecular bone was found.
Hypocalcemia was observed in the 0.50%-Sr group (Table 2) . This phenomenon has also been reported by several other investigators in strontium-fed rats (4, 5, 7, 12) . When rats are subjected to calcium deprivation of various intensities, the decreased calcium intake results in decreased intestinal calcium absorption (Vna) (16) . If only Vna is reduced, then the lack of calcium can be com pensated for by increased bone resorption (Vo-) (17) . However, in the present experiment, both Vna and Vo were reduced in the 0.50%-Sr group. At this level of stron tium, the reduction in Vo may make it impossible to com pensate for the reduced Vna, which may lead to hypocal cemia ( Table 2) .
Bone modeling and remodeling generally occurs by the following process: First, cartilage provides scaffolding for bone formation. The cartilage is then replaced by trabecu lar bone. Finally, the marrow cavity starts to increase in length as minerals are removed. If the final step is block ed, trabecular bone remains without the formation of a marrow cavity. In fact, a large amount of trabecular bone was observed radiographically in the 0.50%-Sr group (Fig. 4) , which might be a consequence of the decreased Vo (Fig. 2e) . Since the decreased Vo would result in both hypocalcemia and an increase in trabecular bone, strontium intake of 875 pmol per day (0.50%-Sr group) may be considered the toxic level.
In this experiment, serum strontium levels increased dose-dependently (Fig. 3a) . There were no changes in serum calcium levels, Vo +, Vo or in the amount of trabecular bone observed radiographically when the se rum strontium concentration was less than about 175 riM, as was the case in the 0.05% and 0.10%-Sr groups. In the 0.50%-Sr group, in which the serum strontium concentra tion was about 550 pM, hypocalcaemia and a large amount of trabecular bone were observed. In this experi ment, the effects of strontium were not studied using se rum strontium levels between 175 and 550 pM. Marie et al. (12) demonstrated an augmentation of trabecular bone volume without any changes in serum calcium concentra tion when rats were treated with strontium for 9 weeks. The dosage of strontium used in their study was between 0.1% and 0.5% in drinking water. They measured serum calcium and strontium at 4 and 9 weeks in the same rats. In their study, the serum strontium concentration dropped from approximately 350 pM at week 4 to 200 pM at week 9, and hypocalcaemia was observed at week 4. Although the serum strontium level at week 9 in their study was similar to the result observed in the present study for the 0.1%-Sr group, the level observed at week 4 in their study was at the toxic level. Therefore, the aug mentation of trabecular bone volume in their study may have resulted from a decreased bone resorption at week 4, and the skeletal change persisted despite a recovery of se rum calcium at week 9. Thus, a serum strontium level of 350 pM might inhibit calcium metabolism.
Strontium retention in bone increased in a dose-depend ent manner (Fig. 3, b and f) . In the 0.50%-Sr group, cal cium retention in the body (Vd) decreased (Fig. 2f) ; however, the bone length did not change (Table 2) . Ac cordingly, although the calcium contents in ashed-femur decreased by 20%, the sum of calcium and strontium, on a molar basis, did not change, as compared with the con trol group (Table 2) . These results suggest that the decrease in calcium was due to an increased content of strontium in newly-formed bone in the 0.50%-Sr group. Rats in the 0.05 %-Sr group, which consumed 87.5 pcmol of strontium per day, showed slight but significant in creases in calcium contents in dried and ashed-bone. At this level of strontium, the strontium level in bone was about 1 % of that of calcium, on a molar basis (Table 2) ; and the serum strontium concentration was about 68 pM. Since strontium intake greater than that in the 0.10%-Sr group does not affect serum parathyroid hormone, calci tonin (4) or la,25-dihydroxyvitamin D3 (12) concentra tions, the increased calcium in bone was not believed to be due to hormonal changes. At a similar concentration of serum strontium, no effects were observed in histologi cal (17) and morphometric (18) studies in rats and mice, respectively. Nevertheless, the increase in the calcium level in bone may be too small to be detected by metabolic or histological analyses. Thus the mechanism of increase in calcium in bone is unclear.
Low doses of strontium have been used for medicinal treatment. McCaslin and Janes (11) reported that marked subjective improvement was experienced by 80% of patients with osteoporosis who had been treated with strontium. In addition, serum strontium concentrations of approximately 60 pM decreased bone pain and in creased mineralization, as observed radiographically, in patients with metastatic bone cancer (10) . Furthermore, a similar beneficial effect of strontium on bone resorption was also found in our previous in vitro study (5) . When newborn mice were injected with strontium for 5 days so that this element would accumulate in calvariae, the en hancement of bone resorption with parathyroid hormone in organ culture was suppressed. When the suppression was observed with a minimum dose of strontium, the strontium/calcium ratio, in terms of molarity, was about 1 % (5). In the present experiment, the strontium levels in bone and serum in the 0.05%-Sr group were similar to those observed by Izumisawa et al. (5) and Skoryna and Fuskova (10) , respectively. At low doses, the beneficial effects of strontium may appear more clearly in skeletal diseases or experimental models in cases where bone turnover is enhanced by ovariectomy, osteoporosis or metastatic bone cancer. In these cases, strontium may be able to restore bone turnover to normal levels. In fact, both Vo+ and Vo increased in ovariectomized rats, but high bone turnover was not observed in ovariec tomized rats that had been fed 87.5 pmol/day of stron tium (unpublished observation, T. Morohashi).
In conclusion, strontium did not alter calcium metabo lic parameters in the 0.10%-Sr group; Therefore, stron tium at doses of less than 175 pmol per day does not ap pear to have toxic effects. Since calcium contents in ashed and dried-femur increased in the 0.05 °Io-Sr group, 87.5 pmol/day of strontium may have some beneficial effects in skeletal diseases in experimental animals.
